Discovery of the Philadelphia chromosome [2,3] and the BCR–ABL1 gene [4] and the development of tyrosine kinase inhibitors made a quantum leap in the treatment of CML. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.